Trial Profile
A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs BMS-986249 (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Advanced breast cancer; Liver cancer; Male breast cancer; Malignant melanoma; Prostate cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 09 Feb 2024 This trial has been completed in Poland, according to European Clinical Trials Database record.
- 04 Jan 2024 This trial has been completed in Finland, according to European Clinical Trials Database record.
- 26 Oct 2023 This trial has been completed in Poland.